MedTrace Logo

Spinal Cord Injury Neuroprotection With Glyburide

NCT02524379 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-07-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety of using oral Glyburide in patients with acute traumatic cervical spinal cord injuries (SCI).

Conditions

  • Acute Spinal Cord Injury

Interventions

DRUG

Glyburide

3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • H. Francis Farhadi, MD, PhD · Ohio State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-14
Primary Completion
2021-02-08
Completion
2021-02-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02524379 on ClinicalTrials.gov